CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
优化基于 CAR-T 细胞的治疗策略以增强胶质母细胞瘤治疗抗肿瘤疗效的研究进展
英文原题：Advances in the Optimization of CAR-T-Cell-Based Therapeutic Approaches to Enhance Antitumor Efficacy in Glioblastoma Treatment.
查看英文原题
Advances in the Optimization of CAR-T-Cell-Based Therapeutic Approaches to Enhance Antitumor Efficacy in Glioblastoma Treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）-T细胞疗法正逐渐成为一种有前景的免疫治疗模式，用于改善高级别胶质瘤的临床结局。近期三项研究已证实颅内CAR-T 细胞给药在胶质母细胞瘤（GBM）患者中的安全性和可行性，并提供了快速但短暂客观缓解的初步证据。这些发现为该方法进一步的临床研究提供了依据。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising immunotherapeutic modality for improving clinical outcomes in high-grade gliomas. Three recent studies have demonstrated the safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM), along with preliminary evidence of rapid but transient objective responses.
These findings provide a rationale for further clinical investigation of this approach.
论文信息
- 作者
- Gatto L、Di Nunno V、Tosoni A、Aprile M、Argento CM、Margotti M、Bartolini S、Franceschi E
- 单位
- Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy. lidia.gatto83@gmail.com.Italy
- 文献类型
- 社论
- 期刊
- Oncology and therapy2025 Sep
- 原文标识
- PubMed 40542937 · DOI 10.1007/s40487-025-00355-1
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →